Alembic Pharmaceuticals' revenue performance in Q2FY24 has shown positive growth. The Company reported an 8.1% increase in consolidated revenue from operations, reaching INR 15,949 Mn, compared to INR 14,750 Mn in Q2FY23. The ex-US generic business saw a healthy growth of 17.2% YoY (-5.4% QoQ) to INR 2,520 Mn, driven by strong market demand and partnerships.